Pembrolizumab 25 MG/ML [Keytruda]
C/41/2021
Phase 3 small_molecule active
Quick answer
Pembrolizumab 25 MG/ML [Keytruda] for Lung Cancer, Nonsmall Cell is a Phase 3 program (small_molecule) at United Therapeutics Europe Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- United Therapeutics Europe Ltd
- Indication
- Lung Cancer, Nonsmall Cell
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active